Company intelligence / Profile preview

TIRX

Boulder, Colorado, USA

Ownership: Private
Development stage: Other

Overview

Tirx Pharma was a Boulder, Colorado-based biotechnology company specializing in the development of targeted oncology therapeutics. The company focused on small molecule inhibitors of Polo-like kinase 1 (Plk1), a key regulator of mitosis that is frequently dysregulated in human cancers. By leveraging research from the University of Colorado Boulder, Tirx aimed to create more selective and less toxic Plk1 inhibitors compared to first-generation candidates. In 2013, the company was acquired by Ligand Pharmaceuticals, which sought to advance the Plk1 program through its internal development and licensing model.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

University of Colorado Boulder

Beyond the preview

Go deeper on TIRX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TIRX.

Explore the full profile